<DOC>
	<DOCNO>NCT01830920</DOCNO>
	<brief_summary>The purpose study determine whether THR-184 administer around time cardiac surgery require cardiopulmonary bypass prevent ameliorate development acute kidney injury .</brief_summary>
	<brief_title>A Study THR-184 Patients Risk Developing Cardiac Surgery Associated-Acute Kidney Injury ( CSA-AKI )</brief_title>
	<detailed_description>The study design include patient schedule cardiac surgery consider increase risk develop CSA-AKI . The eligibility criterion intend enrich study population patient . Stage 1 consisted 140 patient randomize 1:1:1:1 ratio ( approximately 35 patient per treatment arm ) Placebo one three ( 3 ) THR-184 dose arm : - initial pre-surgery low dose THR-184 three ( 3 ) post-surgery dos low dose , - initial pre-surgery middle dose THR-184 follow three ( 3 ) post-surgery dos low dose , - initial pre-surgery high dose THR-184 follow three ( 3 ) post-surgery dos low dose An interim analysis ( IA ) perform Independent Statistical Center ( ISC ) present Independent Data Monitoring Committee ( IDMC ) . The IDMC indicate safety concern recommend study continue placebo arm initial pre-surgery high dose arm . Additionally , another dose arm add , increase dose post-surgery . Stage 2 consist approximately 270 patient randomize 1:1:2 ratio Placebo dose select one two ( 2 ) THR-184 dose arm : - initial pre-surgery high dose THR-184 , follow ( 3 ) post-surgery dos original low dose ; - initial pre-surgery high dose THR-184 , follow ( 3 ) post-surgery dos ~80 % pre-surgery dose Study treatment ( THR-184 placebo ) consist one 60-minute IV infusion administer prior surgery , follow 60-minute IV infusion administer , begin early post-operative period , follow two ( 2 ) additional 60-minute IV infusion administer , consecutive day post-cardiac surgery . The primary endpoint evaluation efficacy patient receive THR-184 , compare patient receive Placebo , proportion patient develop CSA-AKI measure Kidney Disease Improving Global Outcomes ( KDIGO ) criterion , follow : - Increase Serum creatinine ( SCr ) ≥0.3 mg/dl ( &gt; 26.5 µmol/l ) within 48 hour post-surgery ; - Increase SCr ≥1.5 time baseline measure previous 7 day ; - Urine volume &lt; 0.5 ml/kg/h 6 hour post-operatively If least one measure present 7 day assessment , patient consider develop CSA-AKI .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<criteria>Male female &gt; 18 year age . Scheduled nonemergent coronary and/or valve surgery procedure require CPB , include : coronary artery bypass graft ( CABG ) alone ; aortic valve replacement repair alone , without aortic root repair ; mitral , tricuspid , pulmonic valve replacement repair alone ; simultaneous replacement several cardiac valve ; CABG aortic , mitral , tricuspid , pulmonic valve replacement repair ; CABG combine cardiac valve replacement repair . Have follow risk factor CSAAKI : eGFR ≥ 20 &lt; 30 ml/min/1.73m2 OR eGFR ≥ 30 &lt; 60 ml/min/1.73m2 ONE follow additional risk factor ( age ≥ 75 year ) OR eGFR ≥ 60 ml/min/1.73m2 TWO follow additional risk factor Additional Risk Factors : Age ≥ 75 year ; Combined valve &amp; coronary surgery ; Previous cardiac surgery sternotomy ; Documented NYHA Class III IV within 1 year prior surgery ; Left ventricular ejection fraction ( LVEF ) ≤ 35 % invasive noninvasive diagnostic cardiac imaging echocardiography , nuclear imaging , compute tomography , magnetic resonance imaging angiography perform within 90 day prior surgery . ( If LVEF ≤ 35 % invasive noninvasive imaging procedure , patient meet risk factor . ) Insulinrequiring diabetes ; Noninsulinrequiring diabetes presence ≥+2 proteinuria urinalysis ( medical history dipstick ) ; Preoperative anemia ( hemoglobin &lt; 11g/dl men woman ) . If follow criterion apply prior surgery , patient exclude study : Age &gt; 85 year ; Weight &gt; 174 kg 383 lb ; The presence AKI ( KDIGO criterion ) time screen ; Surgery perform without CPB ; Surgery perform condition circulatory arrest hypothermia rectal temperature &lt; 28°Celsius ( 82.4° Fahrenheit ) ; eGFR ( MDRD ) &lt; 20 ml/min/1.73m2 ; Surgery aortic dissection ; Surgery correct major congenital heart defect ( e.g. , Tetralogy Fallot , transposition great vessel , single ventricle , Ebsteins anomaly . Bicuspid aortic valve consider congenital heart defect . ) ; Prior organ transplantation ; Dialysisdependence ; Administration iodinate contrast medium within 24 hour prior cardiac surgery ; If receive contrast medium prior 24 hour AKI define KDIGO criterion ; Cardiogenic shock haemodynamic instability within 24 hour prior surgery , include anesthesia induction period ; define systolic BP &lt; 80 mm Hg pulse &gt; 120 beat per minute ( bpm ) requirement inotropes vasopressor mechanical device intraaortic balloon counterpulsation ( IABP ) ; Requirement follow within seven ( 7 ) day prior cardiac surgery : defibrillator permanent pacemaker , mechanical ventilation , intraaortic balloon counterpulsation ( IABP ) , leave ventricular assist device ( LVAD ) , form mechanical circulatory support ( MCS ) ; Cardiopulmonary resuscitation within 14 day prior cardiac surgery ; Known history cancer within past 5 year , except carcinoma situ cervix adequately treat basal cell carcinoma skin ; Known suspect sepsis time screening ; Known suspect glomerulonephritis interstitial nephritis time screen ; Confirmed treat endocarditis within previous 30 day prior cardiac surgery ; Other current active infection require antibiotic treatment ; Patients know active human immunodeficiency virus infection ; Documented history HIV antibody ; Patients know active Hepatitis B ( HBV ) Hepatitis C ( HCV ) infection ; Documented history HCV antibodies ; Documented history HBV antigens ; Patients immunosuppressant drug prednisone dose 20 mg per day ; Inadequate hepatic function , define total bilirubin alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2 time upper limit normal ( ULN ) time screen Child Pugh Class C liver disease ( see appendix 6 ) high ; Any congenital coagulation disorder ; Pregnancy lactation ; If patient `` Do Not Resuscitate '' ( DNR ) status ; Known hypersensitivity study drug excipients ; Treatment investigational drug participation interventional trial within 60 day prior 1st dose study drug ; In opinion investigator disease process confound variable would inappropriately alter outcome study ; Inability comply requirement study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Acute Kidney Injury</keyword>
	<keyword>AKI</keyword>
	<keyword>Cardiac surgery</keyword>
</DOC>